Brind.

Fulgent Genetics and Agilon Health Classified as Small-Cap Healthcare Firms

1 report, 1 independent Updated Oct 15
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Fulgent Genetics and Agilon Health have been classified as small-cap healthcare companies. A comparison of the two businesses showed that Fulgent Genetics has higher earnings but lower revenue than Agilon Health. Fulgent Genetics is currently trading at a lower price-to-earnings ratio than Agilon Health.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differences in financial metrics, such as institutional ownership and profitability, between the two firms. Fulgent Genetics holds 48.1% of its shares by institutional investors, while Agilon Health holds 36.2% of its shares by institutional investors, suggesting differing levels of external confidence in the companies' growth potential.

From tickerreport.com

Who's involved

  • Fulgent GeneticsBiotechnology company whose financial metrics and valuation were compared.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped